Skip to main content

Center for Molecular Medicine to Provide Genotyping Services for COG Leukemia Study

NEW YORK (GenomeWeb News) - The Center for Molecular Medicine will provide genotyping and analysis services to the Children’s Oncology Group to support a study of genetic abnormalities and their association with response to therapies for treatment of childhood leukemia, CMM said today.
 
CMM, based in Grand Rapids, Mich., said that in the first phase of the study it will analyze up to 2,200 matched samples of DNA from pediatric leukemia patients’ blood samples and their leukemic blasts. The aim is to identify and catalog genetic variations that COG can use in its efforts to develop improved diagnostics and therapeutics for childhood leukemia.
 
CMM will “identify and catalog about a million key SNPs” in these samples, said CMM executive director Daniel Farkas.
 
CMM said it will begin testing samples this month, and that Phase I may be completed by spring.
 
COG and CMM are also “working together to identify sources of funding to expand the study to six to eight thousand more specimens,” CMM said in a statement.
 
Financial terms of the agreement were not released.
 
CMM is a clinical diagnostics laboratory formed last year as a joint venture between Spectrum Health and Van Andel Institute.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.